- Home
- LVLU vs APM Comparison
LVLU vs APM Comparison
Compare LVLU & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- APM
- Stock Information
- Founded
- LVLU 1996
- APM 2010
- Country
- LVLU United States
- APM United Kingdom
- Employees
- LVLU N/A
- APM N/A
- Industry
- LVLU Catalog/Specialty Distribution
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- APM Health Care
- Exchange
- LVLU Nasdaq
- APM Nasdaq
- Market Cap
- LVLU 15.8M
- APM 18.9M
- IPO Year
- LVLU 2021
- APM 2018
- Fundamental
- Price
- LVLU $4.40
- APM $1.50
- Analyst Decision
- LVLU Hold
- APM
- Analyst Count
- LVLU 1
- APM 0
- Target Price
- LVLU $15.00
- APM N/A
- AVG Volume (30 Days)
- LVLU 32.9K
- APM 404.0K
- Earning Date
- LVLU 11-12-2025
- APM 04-30-2025
- Dividend Yield
- LVLU N/A
- APM N/A
- EPS Growth
- LVLU N/A
- APM N/A
- EPS
- LVLU N/A
- APM N/A
- Revenue
- LVLU $292,337,000.00
- APM N/A
- Revenue This Year
- LVLU N/A
- APM N/A
- Revenue Next Year
- LVLU $2.53
- APM N/A
- P/E Ratio
- LVLU N/A
- APM N/A
- Revenue Growth
- LVLU N/A
- APM N/A
- 52 Week Low
- LVLU $2.98
- APM $0.46
- 52 Week High
- LVLU $28.05
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- LVLU 42.81
- APM 40.82
- Support Level
- LVLU $4.45
- APM $1.47
- Resistance Level
- LVLU $4.88
- APM $1.68
- Average True Range (ATR)
- LVLU 0.43
- APM 0.24
- MACD
- LVLU -0.13
- APM -0.06
- Stochastic Oscillator
- LVLU 0.58
- APM 8.74
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.